NewVac LLC
๐ท๐บRussia
Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy
Phase 2
Completed
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2016-10-28
- Last Posted Date
- 2018-06-27
- Lead Sponsor
- NewVac LLC
- Target Recruit Count
- 31
- Registration Number
- NCT02948075
- Locations
- ๐ท๐บ
State Budget Agency of Stavropol Territory Healthcare Pyatigorsk Oncologic Dispensary, Pyatigorsk, Russian Federation
๐ท๐บMedical Radiological Scientific Center n.a. A.F. Tsyb - branch of Federal State Budget Agency "Public Medical Scientific Radiology Center" of Ministry of Health of Russian Federation, Obninsk, Russian Federation
๐ท๐บFederal State budget Scientific Agency "Russian Oncological Research Center n.a. N.N. Blokhin", Moscow, Russian Federation
Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy
Phase 1
Completed
- Conditions
- Non-small Cell Lung CancerEpithelial Ovarian Cancer
- Interventions
- First Posted Date
- 2016-04-05
- Last Posted Date
- 2016-05-03
- Lead Sponsor
- NewVac LLC
- Target Recruit Count
- 51
- Registration Number
- NCT02728492
- Locations
- ๐ท๐บ
BioEq LLC, Saint-Petersburg, Russian Federation
๐ท๐บRussian Oncological Research Center n.a. N. N. Blokhin RAMS, Moscow, Russian Federation
๐ท๐บState Healthcare Institution of Yaroslavl region "Regional Clinical oncology hospital", Yaroslavl, Russian Federation
ยฉ Copyright 2025. All Rights Reserved by MedPath